Steve Schonfeld’s Enveric Biosciences ENVB Stock Holding History

Steve Schonfeld’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2	Closed	-$62K	–	2038
2021 Q1	$62K	Buy	+2	New	+$69.9K	﹤0.01%	1710

Other funds holding ENVB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

EGM

Engineers Gate Manager New York $7.71B AUM 24.88% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Steve Schonfeld's ENVB Position: Q2 2021 in Review

Steve Schonfeld sold out of Enveric Biosciences (ENVB) in Q2 2021, closing a stake of 2 shares — an estimated $62K sold.

Steve Schonfeld first reported a position in ENVB in Q1 2021 and held it in 1 quarter. The position peaked at $62K in Q1 2021. 14 funds tracked by Wall St. Rank hold ENVB as of Q2 2021.

Steve Schonfeld reported no remaining Enveric Biosciences position as of Q2 2021 after selling out during the quarter.
Steve Schonfeld sold 2 Enveric Biosciences shares in Q2 2021, an estimated $62K.
Steve Schonfeld first reported a position in Enveric Biosciences in Q1 2021 and held it in 1 quarter.
Steve Schonfeld's Enveric Biosciences position peaked at $62K in Q1 2021.
14 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.